Become A Featured Company

Havn Life Sciences Undertakes One of the First Preclinical Studies on Psilocybin and the Immune System

Ryan Allway

December 14th, 2020

Psychedelics

Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (“Havn Life”), a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, is pleased to announce the first preclinical study to focus on the effects of psilocybin on the immune system, in partnership with Dr. Geoffrey Bove, Dr. David Mokler and Susan Chapelle, eMBA.

The Company’s science division, Havn Research, is undertaking a study to determine if a single dose of psilocybin extract can impact the body’s inflammatory response and regulate the human immune system.

The Havn Life team will begin this preclinical study in Q1 2021. This study is the first step required to file an application for the development of psilocybin delivery methods that could address inflammatory and immune diseases such as arthritis.

Vic Neufeld, Executive Chairman of Havn Life stated: “We are tremendously excited about the potential to accelerate drug discovery and patient access to psilocybin based compounds. Upon completion of this initial phase, the Havn Life team will have taken the first step on its journey towards market authorization of new medicines. We intend to pursue the filing of an FDA application for psilocybin-based delivery methods, which may ultimately lead to new drug discovery. To date, minimal research has been done on psilocybin and its effects on human immunity, which is an area that has become more and more important.”

Although there is discussion related to the possible effects of psilocybin on inflammation, there has been no research on psilocybin’s impact on the immune system. This will be the one of the first studies to quantify the effects of psilocybin on the immune system and will also compare the differences in how psilocybin affects the immune system between the sexes.

“This is an exciting new application for psilocybin that has not yet been researched. The work is essential to understanding the safety profile of psilocybin and developing medicines to help support human health,” says Susan Chapelle. “The findings could lead to significant discoveries in the treatments of inflammatory diseases that have a profound negative effect on so many, such as pain, neuropathy and arthritis.”

About the Study

The Havn Life study will be conducted in the United States at Dr. Bove’s biomedical centre, in Maine.

The principal researchers will be Doctor Geoffrey Bove, Doctor David Mokler, and Susan Chapelle, EVP of Research and Development at Havn Life, who each have extensive clinical experience in wound healing, pain receptors, psychedelic and pharmacology research. They jointly published a research paper on post-operative adhesions in 2017. The study findings laid the groundwork for further research on mechanical and pharmacologic approaches for post-operative.

Doctor Mokler, is an advisor for Havn Life and has a dual doctorate Pharmacology/Toxicology and Neurosciences from Michigan State University. His research, funded by the National Institute of Mental Health, focuses on the limbic (emotion/behavior) system of the brain, and the role of serotonin in the limbic system.

Susan Chapelle, eMBA is an expert in wound healing and has co-authored 6 publications in peer reviewed journals. She is a noted international Keynote Speaker and industry expert on research, science education, urban transformation, cannabis and psychedelics policy, and technology integrations.

Geoffrey Bove, DC PhD is a career neurobiologist and chiropractor who researches pain mechanisms, especially as related to physical diagnosis and manual therapies. He has been independently funded by the National Institutes of Health and other institutions for 30 years. Previously faculty at Harvard Medical School, Dr. Bove conducts research at his private laboratory, Bove Consulting.

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural healthcare products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading